Study of INCB123667 in Subjects With Advanced Solid Tumors (NCT05238922)
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy and in Combination With Anticancer Therapies in Participants With Selected Advanced Solid Tumors
🩺 Plain-English Summary (8th-Grade Level)
This is an open-label, dose-escalation and dose-expansion study to determine the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy of INCB123667 when administered as monotherapy and in combination with anticancer therapies in participants with selected advanced or metastatic solid tumors. This study will consist of 2 parts. In Part 1, INCB123667 will be administered as monotherapy and in Part 2, INCB123667 will be administered in combination with anticancer therapies of interest. Each part will comprise a dose escalation portion (Parts 1a and 2a, respectively) and a dose-expansion portion (Parts 1b and 2b, respectively).
Who can join: Review the eligibility criteria below.
Location: City of Hope Medical Center — Duarte, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (41 Sites)
Showing the first 25 of 41 sites.
- City of Hope Medical Center — Duarte, California
- City of Hope-Lennar Foundation Cancer Center — Irvine, California
- Valkyrie Clinical Trials — Los Angeles, California
- Rocky Mountain Cancer Centers-Sky Ridge — Lone Tree, Colorado
- Yale Cancer Center — New Haven, Connecticut
- Mount Sinai Medical Center Comprehensive Cancer Center — Miami Beach, Florida
- Emory University — Atlanta, Georgia
- Memorial Sloan Kettering Cancer Center — New York, New York
- New York Presbyterian/Weill Cornell — New York, New York
- Ny Cancer and Blood Specialists — Shirley, New York
- Carolina Bio-Oncology Institute, Pllc — Huntersville, North Carolina
- University of Pennsylvania Abramson Cancer Center — Philadelphia, Pennsylvania
- University of Pittsburgh Cancer Institute Cancer Services — Pittsburgh, Pennsylvania
- Allegheny Health Network — Pittsburgh, Pennsylvania
- Tennessee Oncology — Nashville, Tennessee
- Texas Oncology-Fort Worth South Henderson — Fort Worth, Texas
- Virginia Cancer Institute — Fairfax, Virginia
- University of Wisconsin — Madison, Wisconsin
- Institut Bergonie — Bordeaux,
- Centre Leon Berard — Lyon,
- Universitaire Du Cancer de Toulouse Institut Claudius Regaud Iuct-Oncopole — Toulouse,
- Institut Gustave Roussy — Villejuif,
- Fondazione Irccs Istituto Nazionale Dei Tumori — Milan,
- Istituto Nazionale Tumori Irccs Fondazione Pascale — Naples,
- Policlinico Universitario Agostino Gemelli Universita Cattolica Del Sacro Cuore — Rome,
📞 Contact the Study Coordinator
Phone: (800) 826-4673
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Solid Tumors
- Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors — Basking Ridge, New Jersey
- Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours — Edmonton, Alberta
- Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor) — Santa Monica, California
- A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial — Porto Alegre, Rio Grande do Sul
- Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors — Los Angeles, California
- Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors — Phoenix, Arizona
Explore by condition: All Solid Tumors clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.